Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COM902 in Advanced Malignancies
NCT04354246Phase 1Completed
- Sponsor
- Compugen Ltd.
- Start
- Mar 2020
- Primary completion
- Apr 2026
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of COM902 in cancer, ovarian cancer, lung cancer and 5 more (6 arms), sponsored by Compugen Ltd. Primary endpoints: Safety and tolerability of COM902 monotherapy and in combination with COM701 at 21 days, Maximum tolerated dose (MTD) and/or recommended dose for expansion at 18 months and 3 more. Started Mar 2020; status: completed.
02
Drugs
COM902
03
Conditions
cancerovarian cancerlung cancercolon cancerplasma cell neoplasm
Beyond the preview
Go deeper on NCT04354246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04354246.